Clover

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…

The state of the hunt:

The United Kingdom issued emergency authorization of Pfizer/BioNTech’s vaccine.
  WHO is reviewing the Pfizer/BioNTech shot for Emergency Use Listing.
  Moderna requested emergency nods for its mRNA-based vaccine from the U.S. FDA and the European Medicines Agency.

 

Vaccines


Approved or authorized vaccines

Pfizer is now seeking full British marketing authorization for its Covid-19 vaccine “in parallel” with the…

The state of the hunt:

CEPI expanded its funding for Clover Biopharmaceuticals’ S-Trimer Covid-19 vaccine candidate to $328 million.
  Humanigen touted positive interim Phase 3 results for lenzilumab and announced a cooperative R&D deal with the U.S. government.
  Russia approved a domestic version of Fujifilm’s Avigan for coronavirus outpatients, dubbing the product “the first [f]avipiravir-based drug in the world approved for the treatment of COVID-19.”

 

The state of the hunt:

Gavi made a preliminary deal with GSK and Sanofi, securing up to 200 million doses of their vaccine candidate for the COVAX Facility.
  British regulators began expedited reviews of vaccines from AstraZeneca and Pfizer, and South Korea also began an initial review of the AstraZeneca candidate.
  A trial of an investigational Lilly mAb failed against advanced Covid-19 cases, and a trial of a Regeneron mAb cocktail in people requiring high-flow…

The state of the hunt:

Gilead says remdesivir showed 62% reduced mortality in severe patients
  Sinovac received approval to commence Phase 3 vaccine studies in Brazil
  Pfizer CEO hopes for October FDA vaccine approval
  Hep C drugs sofosbuvir and daclatasvir showed “provocative and encouraging” results against Covid-19

 

Vaccines

Clinical trials:

Brazil regulators approved a Phase 3 trial of Beijing-based Sinovac’s inactivated vaccine…

Announcements of product development initiatives have come fast and furious this week after China earlier this month released to researchers the genetic code of the novel coronavirus (2019-nCoV) originating in Wuhan, and just as WHO today declared the outbreak a Public Health Emergency of International Concern.

Vaccines

Commitments to 2019-nCoV vaccines dominated headlines with the Coalition for Epidemic Preparedness Innovations (CEPI) leading the slew of press releases by…